路透上海6月30日 - Innovent Biologics（1801.HK）周二宣布，该公司已签署一项协议，获得礼来公司（Eli Lilly）旗下 LLY.N 研发的乳腺癌药物Verzenios在中国大陆的独家商业化权。
礼来公司在声明中表示，将继续负责该药物的生产、供应和研发。
路透上海6月30日 - Innovent Biologics（1801.HK）周二宣布，该公司已签署一项协议，获得礼来公司（Eli Lilly）旗下 LLY.N 研发的乳腺癌药物Verzenios在中国大陆的独家商业化权。
礼来公司在声明中表示，将继续负责该药物的生产、供应和研发。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.